In his post, Makary said, “FDA will take swift action against companies’ mass-marketing illegal copycat drugs, claiming they ...
In a lean biotech environment with aggressive milestones, teams often accept reporting that is “good enough.” But those ...
FDA has approved Vybrique, the first oral film formulation of sildenafil for the treatment of erectile dysfunction, offering ...
Veradermics Inc., a late clinical-stage biopharmaceutical company focused on hair restoration, raised $256.3 million in an ...
TrumpRx operationalizes most-favored-nation pricing largely via coupon cards redeemable at pharmacies or through manufacturer ...
In today’s Pharmaceutical Executive Daily, FDA approves Vybrique for erectile dysfunction, experts argue Phase III clinical ...
In today’s Pharmaceutical Executive Daily, TrumpRx officially launches, the FDA moves against mass marketing of illegal copycat drugs, and AI emerges as a force multiplier for small and mid-size ...
By giving small and mid-size biotechs access to real-world data and advanced analytics once reserved for large pharma, AI ...
Novo Nordisk is debuting its first-Super Bowl commercial to promote its newly launched once-daily Wegovy pill, an oral formulation of semaglutide for adults with obesity or overweight with related ...
The FDA rejected AstraZeneca's subcutaneous Saphnelo application, delaying U.S. approval until 2026, despite positive ...
SanegeneBio and Genentech entered a global licensing agreement aimed at advancing an RNA interference (RNAi) therapeutic ...
In today’s Pharmaceutical Executive Daily, Susan G. Komen releases its 2026 breast cancer progress outlook, industry leaders ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results